NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 208 filers reported holding NEKTAR THERAPEUTICS in Q3 2017. The put-call ratio across all filers is 0.25 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $2,036,000 | +2.3% | 60,589 | +0.1% | 0.45% | -5.8% |
| Q4 2018 | $1,990,000 | +23.7% | 60,549 | +83.7% | 0.48% | +55.0% |
| Q2 2018 | $1,609,000 | -88.8% | 32,960 | -75.6% | 0.31% | -88.4% |
| Q1 2018 | $14,378,000 | +263.7% | 135,312 | +104.4% | 2.67% | +226.0% |
| Q4 2017 | $3,953,000 | +25.0% | 66,200 | -49.8% | 0.82% | -6.9% |
| Q3 2017 | $3,162,000 | +29.7% | 131,757 | +5.7% | 0.88% | +22.4% |
| Q2 2017 | $2,437,000 | -40.8% | 124,632 | -28.9% | 0.72% | -30.0% |
| Q1 2017 | $4,115,000 | – | 175,315 | – | 1.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 3,500,000 | $60,060,000 | 2.02% |
| ACT CAPITAL MANAGEMENT, LLC | 161,500 | $2,772,000 | 1.42% |
| Rhenman & Partners Asset Management AB | 950,000 | $16,302,000 | 1.11% |
| MAVERICK CAPITAL LTD | 5,761,073 | $98,860,000 | 0.93% |
| Birchview Capital, LP | 72,000 | $1,236,000 | 0.74% |
| Bellevue Group AG | 4,101,404 | $70,380,000 | 0.69% |
| CM Management, LLC | 50,000 | $858,000 | 0.62% |
| Duquesne Family Office | 1,000,000 | $17,160,000 | 0.42% |
| OSTERWEIS CAPITAL MANAGEMENT INC | 373,368 | $6,407,000 | 0.33% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 67,000 | $1,149,000 | 0.30% |